OVERVIEW OF ACTIVITY

Lung cancer is the leading cause of cancer mortality in the United States in both men and women, resulting in more deaths than breast, prostate, colon and pancreatic cancer combined. Progress in the screening, prevention and treatment of this disease has been limited, and about 85 percent of patients who develop lung cancer will die from it. Traditional chemotherapy, surgery and radiation therapy have had a modest effect on patient outcomes. However, with the advent of biologic agents, recent improvements have been seen in time to progression and survival in lung cancer clinical trials. Published results from ongoing and completed studies lead to the continual emergence of novel therapeutic strategies and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. Featuring information on the latest research developments along with experts’ perspectives, this CME program is designed to assist medical oncologists, hematologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies for the care of patients with lung cancer.

LEARNING OBJECTIVES

• Summarize the benefits and risks of alternative surgical approaches for patients with localized or resectable locally advanced non-small cell lung cancer (NSCLC).
• Utilize tumor characteristics and molecular biomarkers in treatment decision-making for patients with lung cancer.
• Communicate the benefits and risks of induction chemotherapy and concurrent chemoradiation therapy when devising treatment strategies for Stage III NSCLC.
• Integrate emerging data on the combined use of cytotoxics and biologics when selecting first-line therapy and subsequent care for patients with advanced NSCLC.
• Identify patients with NSCLC who are most likely to benefit from treatment with EGFR tyrosine kinase inhibitors.
• Appraise the current role of maintenance pemetrexed for patients with advanced NSCLC that responds to front-line chemotherapy.
• Recall the emerging data and ongoing trials evaluating novel targeted agents in lung cancer, and assess the implications for present and future clinical practice.
• Counsel appropriately selected patients with lung cancer about the availability of ongoing clinical trials in which they may be eligible to participate.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should review the CME information, listen to the CDs and complete the Post-test and Educational Assessment and Credit Form located at www.LungCancerUpdate.com/CME. www.LungCancerUpdate.com contains edited comments, clinical trial schemas, graphics and references that supplement the audio program, as well as links to relevant full-text articles, abstracts, trial information and other web resources indicated here in blue underlined text.

This program is supported by educational grants from Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology/OSI Oncology, ImClone Systems Incorporated and Sanofi-Aventis.

Home

EDITOR
Neil Love, MD

INTERVIEWS

David Jablons, MD
- Select publications

Gregory J Riely, MD, PhD
- Select publications

Alan B Sandler, MD
- Select publications

David S Ettinger, MD
- Select publications

Lung Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office